ACP Letter to the Senate Health, Labor, and Pensions (HELP) Committee Offering Feedback to Discussion Draft Of FDA User Fee Agreement Reauthorization

ACP letter to the Senate HELP Committee with feedback on the discussion draft of the FDASLA Act of 2022 that would ensure patient's needs for safe and effective prescription drugs

Robin Chichester

Sen. Patty Murray; Sen. Richard Burr; HELP Committee; Senate Health, Education, Labor and Pensions Committee; HELP; U.S. Food and Drug Administration; FDA; prescription drugs; user fees; user fee programs; User Fee Agreements: Advancing Medical Product Regulation and Innovation for the Benefit of Patients; Prescription Drug User Fee Act; PDUFA; user fee agreements; UFA; Generic Drug User Fee Act; GDUFA; Biosimilar User Fee Act; BsUFA; medications; generics; biologics; biosimilar drugs; pharmaceutical companies; vaccines; supply chain; drug pricing; transparency; direct-to-consumer advertising; pay-for-delay practices; evergreening; product-hopping; Food and Drug Administration Safety and Landmark Advancements Act of 2022; FDASLA Act of 2022; capacity planning adjustment; CPA; opioids; safe disposal; orphan drugs; Orphan Drug Act

Fri, 05/20/2022 - 9:38 AM EDT

Fri, 05/20/2022 - 11:19 AM EDT

4

acp_letter_to_senate_help_committee_offering_feedback_to_discussion_draft_of_fda_user_fee_agreement_may_2022.pdf

{"Author":"Robin Chichester","CreationDate":"2022-05-20T09:38:50-04:00","Creator":"Microsoft\u00ae Word for Microsoft 365","Keywords":"Sen. Patty Murray; Sen. Richard Burr; HELP Committee; Senate Health, Education, Labor and Pensions Committee; HELP; U.S. Food and Drug Administration; FDA; prescription drugs; user fees; user fee programs; User Fee Agreements: Advancing Medical Product Regulation and Innovation for the Benefit of Patients; Prescription Drug User Fee Act; PDUFA; user fee agreements; UFA; Generic Drug User Fee Act; GDUFA; Biosimilar User Fee Act; BsUFA; medications; generics; biologics; biosimilar drugs; pharmaceutical companies; vaccines; supply chain; drug pricing; transparency; direct-to-consumer advertising; pay-for-delay practices; evergreening; product-hopping; Food and Drug Administration Safety and Landmark Advancements Act of 2022; FDASLA Act of 2022; capacity planning adjustment; CPA; opioids; safe disposal; orphan drugs; Orphan Drug Act","ModDate":"2022-05-20T11:19:54-04:00","Producer":"Microsoft\u00ae Word for Microsoft 365","Title":"ACP Letter to the Senate Health, Labor, and Pensions (HELP) Committee Offering Feedback to Discussion Draft Of FDA User Fee Agreement Reauthorization","Pages":4}

2022